Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Maplight Therapeutics Inc (MPLT)

102 + Investors. Track Smart Money conviction in MPLT. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +24
Streak
3Q ▲
Buyers last Q
59%

Smart Money Signals — MPLT

Based on 103 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q
For 3 consecutive quarters, more hedge funds added MPLT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
103 hedge funds hold MPLT right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +10200% more funds vs a year ago

fund count last 6Q
+102 new funds entered over the past year (+10200% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 59% buying

58 buying41 selling
Last quarter: 58 funds bought or added vs 41 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+16 vs last Q)

new funds entering per quarter
Funds opening a new MPLT position: 0 → 73 → 21 → 37. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 97% entered in last year

■ 2% conviction (2yr+) ■ 1% medium ■ 97% new
Only 2 funds (2%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +78% but shares only +6% — price-driven

Value
+78%
Shares
+6%
Last quarter: the total dollar value of institutional holdings rose +78%, but actual share count only changed +6%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
📊

Peak discovery — momentum slowing

0 → 0 → 73 → 21 → 37 new funds/Q
New funds entering each quarter: 0 → 73 → 21 → 37. MPLT is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🌱

Early stage — 97% of holders entered in last year

■ 3% veterans ■ 0% 1-2yr ■ 97% new
Of 104 current holders: 101 (97%) entered in the past year, only 3 (3%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
✅

Strong quality — 29% AUM from major funds

29% from top-100 AUM funds
32 of 102 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
7.4
out of 10
High Exit Risk
Exit risk score 7.4/10 — multiple crowding signals converge. Institutional ownership is at 100% of its all-time high — near peak crowding. Crowded trades can unwind fast — a single catalyst can trigger a cascade.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MPLT

In 2026 Q2, 58 hedge funds were net buyers of MPLT (37 opened a new position, 21 added to an existing one), while 41 reduced or exited (28 trimmed, 13 sold completely) — a 59% buyer ratio, indicating a slight buying edge. This marks 3 consecutive quarters of net institutional buying — a persistent conviction signal. 29% of total institutional value in MPLT is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +24 funds (more new holders than closures). Total institutional holders: 103.

Hedge Fund Ownership: MPLT

How many hedge funds hold MPLT — quarterly history vs. share price
Quarterly hedge fund ownership of MPLT vs. share price

Market Analysis: MPLT

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MPLT

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Maplight Therapeutics Inc (MPLT) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MPLT has moved relative to its sector benchmark (XLV) since the 2026 Q2 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End June 30, 2026 · 50d ago
MPLT
-68.6%
XLV
+7.1%

MPLT outperformed XLV by -75.7% since June 30, 2026.

Since 13F Filing Date August 14, 2026 · 5d ago
MPLT
-4.3%
XLV
+1.5%

Since the filing became public, MPLT outperformed XLV by -5.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

6 top-rated funds 3 high-conviction
Consensus
3.7
/ 10
breadth
×
Elite
2.8
/ 10
conviction
Hedge Fund Positioning: MPLT
102 + Investors

Track Smart Money conviction in MPLT. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 102 79 29.11%
13F Shares 26M 25M 6.19%
Total Value $789M $443M 78.22%
New Positions 37 21 +16
Increased Positions 21 25 -4
Closed Positions 13 16 -3
Reduced Positions 28 13 +15
Total Calls 0 0 -
Total Puts 2 0 100%
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: MPLT

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q2)

102 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MPLT. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MPLT holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Nan Fung Group Holdings Ltd 26.47% 971,253 $34.8M
2 Fcpm III Services B.V. 15.41% 3,226,400 $115.6M
3 5AM Venture Management, LLC 11.83% 950,011 $34.0M
4 Velan Capital Investment Management LP 10.76% 492,893 $17.7M
5 Novo Holdings A/S 7.67% 3,686,622 $132.1M
6 Pivotal bioVenture Partners Investment Advisor LLC 7.12% 611,446 $21.9M
7 Sanofi 6.12% 912,041 $32.7M
8 Blue Owl Capital Holdings LP 3.94% 729,929 $26.2M
9 Superstring Capital Management LP 2.84% 125,432 $4.5M
10 DAFNA Capital Management LLC 1.17% 171,006 $6.1M
11 Stempoint Capital LP 0.66% 106,906 $3.8M
12 Paradigm Biocapital Advisors LP 0.46% 685,852 $24.6M
13 Siren, L.L.C. 0.33% 450,000 $16.1M
14 Boxer Capital Management, LLC 0.20% 75,000 $2.7M
15 Seven Grand Managers, LLC 0.14% 100,000 $3.6M
16 Virtus Investment Advisers, LLC 0.10% 11,791 $423K
17 Burkehill Global Management, LP 0.10% 75,000 $2.7M
18 Market Street Wealth Management Advisors LLC 0.07% 14,124 $506K
19 Baker BROS. Advisors LP 0.07% 364,705 $13.1M
20 MA Private Wealth 0.06% 10,389 $372K
21 ADAR1 Capital Management, LLC 0.04% 26,497 $950K
22 Freestone Grove Partners LP 0.04% 168,912 $6.1M
23 Bridgeway Capital Management, LLC 0.02% 35,000 $1.3M
24 Ghisallo Capital Management LLC 0.01% 20,000 $717K
25 Trexquant Investment LP 0.01% 63,792 $2.3M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Maplight Therapeutics Inc (MPLT)

What does the Smart Money Trend signal show for MPLT?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added MPLT than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MPLT?

Slight buying edge — 59% buying: Last quarter: 58 funds bought or added vs 41 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MPLT holders?

Strong quality — 29% AUM from major funds: 32 of 102 holders rank in the top 100 by AUM, accounting for 29% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held MPLT?

Mostly new holders — 97% entered in last year: Only 2 funds (2%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Maplight Therapeutics Inc (MPLT) following the 2026 Q2 hedge fund 13F filings?

As of today, MPLT has moved -4.3% since the 2026 Q2 13F filing date (August 14, 2026), compared to +1.5% for the XLV sector ETF — an outperformance of -5.8%. Since the quarter end (June 30, 2026), MPLT has gained -68.6% vs +7.1% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →